Ontology highlight
ABSTRACT: Introduction
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Surgery is the standard of care with curative intent of localized disease; however, for large head and neck cSCCs, it is associated with high morbidity. Cemiplimab, an antibody anti programmed cell death-1 (PD-1) protein, is effective in locally advanced unresectable or metastatic cSCC. A pilot study demonstrated a high rate of pathologic complete response using cemiplimab in the neoadjuvant setting.Case presentation
Here, we report the case of an 84-year-old man with two locally advanced unresectable cSCCs (a nasolabial lesion and a retroauricular lesion) treated with cemiplimab, for whom closer follow-up revealed a complete response of the retroauricular lesion and a partial respo
SUBMITTER: Cabral SC
PROVIDER: S-EPMC11521489 | biostudies-literature | 2024 Jan-Dec
REPOSITORIES: biostudies-literature